title: The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
abstract: The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.
authors.forename: Faith E
authors.initials: FE
authors.lastname: Davies
authors.forename: Ping
authors.initials: P
authors.lastname: Wu
authors.forename: Matthew
authors.initials: M
authors.lastname: Jenner
authors.forename: Muralikrishan
authors.initials: M
authors.lastname: Srikanth
authors.forename: Radovan
authors.initials: R
authors.lastname: Saso
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000378:metabolism; D003907:Dexamethasone / Q000008:administration & dosage / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007239:Infections / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009422:Nervous System Diseases / Q000139:chemically induced; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011719:Pyrazines / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide